Javdani-Mallak Afsaneh, Mowla Seyed Javad, Alibolandi Mona
Department of Molecular Genetics, Faculty of Biological Sciences, Tarbiat Modares University, Tehran, Iran.
Pharmaceutical Research Center, Pharmaceutical Technology Institute, Mashhad University of Medical Sciences, Mashhad, Iran.
J Transl Med. 2025 Jul 8;23(1):751. doi: 10.1186/s12967-025-06814-7.
Tumor-derived exosomes (TDEs) are vesicles characterized by their nanoscale size, secreted through cancer cells to boost the intercellular communications of the tumor microenvironment. TDEs enclose a cocktail of bioactive molecules, such as proteins, lipids, RNA, and DNA, which can encourage angiogenesis, immune evasion, and metastasis to enhance tumor progression. Researchers are now interested in tumor-derived exosomes as markers and potential novel vehicles for the delivery of therapeutics in cancer treatment since they exhibit different molecular profiles and biological functions.
PubMed, Scopus, and Google Scholar were methodically explored for articles estimating the dual functions of TDEs and their potential applications as new therapeutic targets and drug delivery vehicles for the transportation of anti-cancer drugs and immune-modulating compounds.
TDEs represent great promise in advancing cancer diagnostics and therapy through their portrayal in cell communication, tumor regulation, and immune modulation. They offer potential for noninvasive, targeted treatment and early detection. However, standardization, reproducibility, and immune interaction challenges must be addressed. Continued interdisciplinary research is essential to realize their clinical potential fully.
Advancements in exosome engineering denote auspicious alternatives to conventional cancer therapies, with benefits like reduced toxicity and enhanced targeting. Understanding the biology of TDEs implements the development of novel treatments and improves diagnostics, prognostics, and monitoring of cancer progression. Integrating TDE-based tools with personalized medicine credits the potential to transform cancer care by providing more effective and individualized therapies.
肿瘤来源的外泌体（TDEs）是一种具有纳米级尺寸的囊泡，由癌细胞分泌，可促进肿瘤微环境中的细胞间通讯。TDEs包含多种生物活性分子，如蛋白质、脂质、RNA和DNA，它们可促进血管生成、免疫逃逸和转移，从而加速肿瘤进展。由于TDEs表现出不同的分子特征和生物学功能，研究人员现在对其作为癌症治疗中治疗药物递送的标志物和潜在新型载体很感兴趣。
系统检索PubMed、Scopus和谷歌学术数据库，查找评估TDEs双重功能及其作为抗癌药物和免疫调节化合物运输的新治疗靶点和药物递送载体的潜在应用的文章。
TDEs在细胞通讯、肿瘤调节和免疫调节方面具有重要作用，有望推动癌症诊断和治疗的发展。它们具有非侵入性、靶向治疗和早期检测的潜力。然而，必须解决标准化、可重复性和免疫相互作用等挑战。持续的跨学科研究对于充分实现其临床潜力至关重要。
外泌体工程的进展为传统癌症治疗提供了有前景的替代方案，具有降低毒性和增强靶向性等优点。了解TDEs的生物学特性有助于开发新的治疗方法，并改善癌症进展的诊断、预后和监测。将基于TDEs的工具与个性化医疗相结合，有可能通过提供更有效和个性化的治疗方法来改变癌症治疗。
